Atlantic Canada at BIO 2026

Founded in Newfoundland and Labrador nearly 30 years ago, Fonemed is a global virtual healthcare and technology-enabled clinical services organization headquartered in St. John's, NL and Ventura, California, supporting more than 40 million individuals and over 3,300 client groups across Canada, the US, Latin America, and Asia through integrated telehealth, virtual care, and remote clinical support. Its proprietary Florizel platform securely connects patients, clinicians, devices, and monitoring technologies in real time.

Canada-based biotechnology company providing an innovative patented plasmid platform and contract research services for vaccines and biotherapeutics across human and animal health. Pegasus supports clients from discovery through regulatory submissions (EMA, CFIA, FDA, USDA) and deployment, with expertise in DNA, autogenous, recombinant protein, and VLP platforms. Operating from three PEI facilities under an audited QMS, ~90% of projects come from repeat business and referrals.

A leading outsourced business development company focused on partnering, licensing, and M&A transactions globally in pharma, biotech, and medtech. With more than 25 years of expertise and over $3 billion of completed agreements, Partner International's life sciences team has access to decision makers at more than 45,000 companies across 26 countries.

Halifax-developed medical technology company commercializing the world's first urine-based muscle health monitoring test. Launched October 2024 following Health Canada MDEL approval, the test measures proprietary biomarkers to produce a muscle health score — enabling clinicians to detect early-stage muscle degeneration, guide interventions, and track recovery. Backed by a $3.5M seed raise, Invest Nova Scotia's Accelerate program validation, and a growing B2B clinic network across Canada.

Focused on treating and preventing protein misfolding diseases such as Alzheimer's, ALS, and tauopathies like FTD. Its patented Common Conformational Morphology (CCM) platform enables computer-aided design of small-molecule anti-oligomerization agents, validated by strategic partnerships with Takeda (a $372.5M option, license, and collaboration in 2023) and Servier (2018). Treventis operates from Ontario and Nova Scotia.

Clinical-stage biotech based in Dieppe, NB, advancing a first-in-class topical treatment for androgenic alopecia — a condition affecting over 1.4 billion people globally. Its patented Therapy-07 (TH07) triple-combination topical demonstrated hair regrowth in 100% of patients in a proof-of-concept trial. Health Canada and EMA approved for Phase III trials across Canada, Europe, and India, with international licensing already secured including a deal with Brazil's Aché Laboratórios.

Dieppe, NB medtech developing the world's first injectable, office-based implant for minimally invasive glaucoma surgery (MIGS) — a procedure currently requiring a hospital operating room. With no FDA-approved ab-externo MIGS device on the market, Hexiris targets a significant unmet need in a global glaucoma market projected to reach 111 million patients by 2040. The device is designed to be administered at a slit lamp, removing the cost and access barriers of OR-based procedures.

Agilent's specialty CDMO, delivering customized development and manufacturing solutions for advanced therapeutics from development through commercial supply. Capabilities span biologics, synthetic small molecules, nucleic acids (including oligonucleotide therapeutics), highly potent APIs, bioreagents, fill/finish, fermented small molecules, and cell banking. Visit booth #4257 to learn more.

Halifax, NS-based company specializing in developing first-in-class cancer immunotherapies by targeting tumor-specific long non-coding RNAs.

Halifax-based biomaterials manufacturer specializing in the production of biopolymer fibers like collagen, chitosan, and spider silk. Using patent-issued dry spinning technology, 3DBioFibR produces fibers that recapitulate natural structure and mechanics at >3,600x the scale of competing wet spinning and electrospinning. Products include CollaFibR® 3D collagen scaffolds for regenerative medicine and pure collagen yarns for resorbable textile-based medical devices.

Global biotech CRO and CDMO specializing in large molecule drug development including cell and gene therapy, actively exploring in-licensing opportunities for biosimilar drug substances and products. Provides end-to-end bioanalytical support — method development, validation, clinical trial sample analysis (PK, PD, immunogenicity ADA/NAb, ADCC, biomarker studies) — plus a clinical CRO supporting bioequivalence and clinical trials under international standards.

Halifax, Nova Scotia health technology company developing the XO Companion Ring — a wearable platform designed to support functional health monitoring for older adults. The ring continuously captures grip strength, gait, activity patterns, and physiological signals to identify early signs of functional decline. Currently validating in long-term care environments including a pilot with Dykeland Lodge.

The Canadian Alliance for Skills and Training in Life Sciences (CASTL) is Canada's life science training partner, dedicated to developing skilled talent to drive the country's thriving biomanufacturing sector. With GMP-simulated facilities in Charlottetown, Montreal, and Vancouver, CASTL delivers hands-on training alongside flexible online learning, and is Canada's exclusive provider of Ireland's NIBRT programs.

Halifax, NS nanotechnology company developing Targeted Hyperthermia Therapy (THT) for solid tumor cancer treatment, using its patented CTAB-free gold nanorod platform. In a 2025 early human study, THT demonstrated an 80% overall response rate and 60% complete responses in immunotherapy-resistant melanoma. The platform also serves in vitro diagnostics through next-generation multiplex lateral flow assays. Listed on the CSE (SONA).

With over 40 years of experience, SEKISUI Diagnostics' mission is to enhance life with science by supplying innovative medical diagnostics globally to physicians, hospitals, laboratories, and alternate testing locations, alongside partnerships with the world's leading healthcare companies. Product lines include clinical chemistry reagents for cardiac, liver, and general health; point-of-care tests; blood collection tube materials; and enzymes and specialty biochemicals.

Precision developer and contract manufacturer of nanomaterials and DNA/RNA oligonucleotides for therapeutic and diagnostic applications, offering services from proof-of-concept through pilot-scale production. The portfolio includes custom functionalized magnetic nanoparticles, purification/extraction kits, and oligonucleotide synthesis (siRNA, ASO, sgRNA). A member of the Emergence Bioscience Incubator, serving clients globally.